TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01486316

Intervention type: DEVICE
Group type: OTHER
Intervention: Reveal XT® Insertable Cardiac Monitor
Description: If not previously implanted, a non-experimental insertable cardiac monitor will be implanted to collect information on the patients' heart condition as inputs into the heart failure risk status algorithm (during guided follow-up only, Guided arm: 6-18 months, Control arm: 12-18 months).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reveal XT® Insertable Cardiac Monitor
Description: If not previously implanted, a non-experimental insertable cardiac monitor will be implanted to collect information on the patients' heart condition as inputs into the heart failure risk status algorithm (during guided follow-up only, Guided arm: 6-18 months, Control arm: 12-18 months).

Intervention type: OTHER
Group type: OTHER
Intervention: Heart Failure Risk Status Diagnostic
Description: The experimental IDENTIFY-HF Risk Status developed for this study will be used to change standard device data to a heart failure risk status. The risk status and standard device trend data are provided to study doctors for remote management of their patients' heart failure using study specific protocols. The risk status inputs are: night heart rate, heart rate variability, atrial fibrillation burden, ventricular rate during atrial fibrillation, patient activity.~Based on pre-defined thresholds for each of the above inputs, as well as data trends, a heart failure score is derived. The heart failure score is then classified as: Low, Medium, High, or Very High.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Failure Risk Status Diagnostic
Description: The experimental IDENTIFY-HF Risk Status developed for this study will be used to change standard device data to a heart failure risk status. The risk status and standard device trend data are provided to study doctors for remote management of their patients' heart failure using study specific protocols. The risk status inputs are: night heart rate, heart rate variability, atrial fibrillation burden, ventricular rate during atrial fibrillation, patient activity.~Based on pre-defined thresholds for each of the above inputs, as well as data trends, a heart failure score is derived. The heart failure score is then classified as: Low, Medium, High, or Very High.
Study: NCT01829789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Community Reinforcement Training for Parents

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Community Reinforcement Training for Parents
Study: NCT03793179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT04763382

Intervention type: OTHER
Group type: OTHER
Intervention: experimental group: Training of caregivers
Description: Pre-test, post-test, retention test, education, guide booklet delivery, android application installation and urinalysis

Intervention type: OTHER
Group type: OTHER
Intervention: Control gruop
Description: Pre-test, post-test and urinalysis
Study: NCT03793179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study: NCT03197675

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Participants within the acupuncture treatment group will receive traditional body acupuncture with electrical stimulation for 30 minutes three times a week, additionally participants will also receive auricular acupuncture once a week with the needles retained in both ears for seven days and replaced the following week, for a total of eight weeks (24 treatments of conventional acupuncture and 8 treatments of auricular acupuncture). Relative pain levels will be measured via the NRS by a member of the research staff before and after each treatment. All participants will then be reevaluated with the described assessment tools at three months and again at six months. Acupuncturists will not participate in the three and six month evaluations of subjects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Participants within the acupuncture treatment group will receive traditional body acupuncture with electrical stimulation for 30 minutes three times a week, additionally participants will also receive auricular acupuncture once a week with the needles retained in both ears for seven days and replaced the following week, for a total of eight weeks (24 treatments of conventional acupuncture and 8 treatments of auricular acupuncture). Relative pain levels will be measured via the NRS by a member of the research staff before and after each treatment. All participants will then be reevaluated with the described assessment tools at three months and again at six months. Acupuncturists will not participate in the three and six month evaluations of subjects.
Study: NCT03887637

Intervention type: DRUG
Intervention: DAAs
Description: Patients with CHC and cirrhosis who fulfills the indication of antiviral therapy will be administered with DAAs treatment.
Study: NCT03084900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 1
Description: Patient-Centered Decision Support to Improve Diabetes Mgmt. We will use a computerized decision support system to aid clinicians to provide standard of care management while introducing patient-centered guidelines and outcomes measures.The intervention is the use of an electronic decision support tool. The decision support tool consists of a series of questions answered by the patients that will then allow the health care provider to address specific needs during the visit.
Study: NCT03887637

Intervention type: DRUG
Intervention: DAAs
Description: Patients with CHC and cirrhosis who fulfills the indication of antiviral therapy will be administered with DAAs treatment.

Intervention type: DRUG
Intervention: DAAs
Description: Patients with CHC and cirrhosis who fulfills the indication of antiviral therapy will be administered with DAAs treatment.
Study: NCT03793179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study: NCT04698889

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: natural cow

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: high protein cow milk

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: natural human

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low protein cow milk
Study: NCT02518139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208
Description: Subjects receiving TD-4208 are blinded to one of two doses of 4208.
Study: NCT01994720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: ticagrelor, 180 mg (two tablets of 90 mg) loading dose on Day 1 followed by 90 mg twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Description: ASA, 300 mg (three tablets of 100 mg) on Day 1, followed by 100 mg once daily.
Study: NCT00146640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR Prednisone
Description: Participants will receive tablets containing MR prednisone (to achieve the appropriate dose of 3-10 milligrams \[mg\] prednisone per day) at bed time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IR Prednisone
Description: Participants will receive tablets containing IR prednisone (to achieve the appropriate dose of 3-10 mg prednisone per day) in the morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - MR Prednisone
Description: Participants will receive placebo matching to MR prednisone tablet at bed time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - IR Prednisone
Description: Participants will receive placebo matching to IR prednisone tablet in the morning.
Study: NCT01988519

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed gravity drain
Description: passive tube drains (PFM Medical, Köln, Germany)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closed suction drain
Description: BLAKE Silicon drains (Ethicon, USA)
Study: NCT03073629

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Pathway
Description: Patients will be evaluated and managed in a specialized cardiovascular clinic to determine the etiology of right heart failure and begin treatment.
Study: NCT03805464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee Joint Effusion
Description: 60mL saline injection into the supra-patellar region of the knee
Study: NCT01364961

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol capsules
Description: 2 x 75 mg resveratrol each day, for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol capsules
Description: 2 x 75 mg resveratrol each day, for 4 weeks
Study: NCT02821390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac Eye Drops
Description: One drop instilled to the eye's cul de sac prior to the intravitreal injection.
Study: NCT02821390

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Artificial Tears)
Description: One drop instilled to the eye's cul de sac prior to the intravitreal injection
Study: NCT04166695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monolithic / facially veneered zirconia fixed partial denture
Description: Participant receives one monolithic / facially veneered zirconia fixed partial denture retained by either teeth, implants or teeth and implants for the replacement of two neighbouring posterior teeth.
Study: NCT01690234

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Description: Early coordinated multidisciplinary intervention. Physiotherapist, chiropractor, rheumatologist, psychologist, occupational physician, ergonomist and social worker/case manager.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Intervention from physiotherapist, chiropractor, rheumatologist and social worker.
Study: NCT04166695

Intervention type: DEVICE
Group type: OTHER
Intervention: Completely veneered CoCr fixed partial denture
Description: Participant receives one completely veneered CoCr fixed partial denture retained by either teeth, implants or teeth and implants for the replacement of two neighbouring posterior teeth.
Study: NCT04545619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QDOT MICRO System
Description: QDOT Micro Catheter with nGEN Generator
Study: NCT02013687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25 VLP- FhCMB

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25 VLP- FhCMB

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25 VLP- FhCMB

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25 VLP- FhCMB
Study: NCT03291197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suprascapular and median nerve blocks
Description: Ultrasound guided injection of the median and suprascapular nerve of the affected side.
Study: NCT02723162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline (VRN)
Description: VRN will be provided at the standard recommended dose (0.5 mg daily for 3 days, then 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for the remaining 21 days of active treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline (VRN)
Description: VRN will be provided at the standard recommended dose (0.5 mg daily for 3 days, then 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for the remaining 21 days of active treatment.
Study: NCT02046538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 IV over two hours (or administered concurrently with oxaliplatin or irinotecan, depending on the assigned regimen)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 400 mg/m2 IV over two hours (or administered concurrently with oxaliplatin or irinotecan, depending on the assigned regimen)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 IV over two hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/m2 IV over two hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 IV over 90 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m2 IV over 90 minutes
Study: NCT04779164

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: knee ultrasonography
Description: The knees of all patients were screened with ultrasonography device for the measurement of femoral cartilage thicknesses.
Study: NCT02723162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine (NAC)
Description: NAC will be dosed at 1200 mg twice daily throughout the 28-day active treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC)
Description: NAC will be dosed at 1200 mg twice daily throughout the 28-day active treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matched placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT02518139

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: There is not a placebo, there is an active comparator (Tiotropium) arm.
Study: NCT04779164

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: knee ultrasonography
Description: The knees of all patients were screened with ultrasonography device for the measurement of femoral cartilage thicknesses.
Study: NCT04305236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given Intramuscularly
Study: NCT01793246

Intervention type: DEVICE
Intervention: probe based laser endomicroscopy (pCLE)
Description: pCLE will be added to standard bronchoscopy for the purpose of characterizing lung cancer or for characterizing of acute rejection in transplanted lungs.
Study: NCT03598231

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sacral neuromodulation
Description: After the definitive implantation, stimulators are placed in position OFF for the first arm and in position ON for the second arm during 4 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 2 weeks.~Finally stimulators are maintained in position ON for the first arm and switched OFF for the second arm during 4 weeks.~Since this is a cross-over study, patients can be randomly assigned to any arm first, but they will go to the other arm since the patient is its own control. 50% of randomized patients will go through ON-OFF and the other 50% OFF-ON.~After this cross-over phase, ALL stimulators will be in ON position until the end of the study period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral neuromodulation
Description: After the definitive implantation, stimulators are placed in position OFF for the first arm and in position ON for the second arm during 4 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 2 weeks.~Finally stimulators are maintained in position ON for the first arm and switched OFF for the second arm during 4 weeks.~Since this is a cross-over study, patients can be randomly assigned to any arm first, but they will go to the other arm since the patient is its own control. 50% of randomized patients will go through ON-OFF and the other 50% OFF-ON.~After this cross-over phase, ALL stimulators will be in ON position until the end of the study period.
Study: NCT01380496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline monohydrate
Description: tablet, 100 mg, single, oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline monohydrate
Description: Capsule, 100 mg, single, oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline monohydrate
Description: Capsule, 100 mg, single, oral dose
Study: NCT01539434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural intervention
Description: Patients in the behavioural intervention group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active. The behavioural intervention to support physical activity behaviour includes weekly motivational interviewing telephone calls for the first month, two telephone calls for the following two months and thereafter monthly telephone calls.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care group
Description: Patients in the usual care group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active.
Study: NCT04047069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Awareness Training and Person-Centered Occupational Therapy Intervention
Description: Exp. identifying the activities the person wants to do, suggestions to facilitate the activity, arranging the activity according to the needs of the person, arranging the environment so that the environment can be a facilitating factor in the activities the person wants to do.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Awareness Training
Description: Exp.~* General information about HD~* Approaches to Coping with HD Symptoms~* Self care skills (eg hygiene)
Study: NCT03806296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increase morning bright light
Description: Participants will wear Re-Timer bright glasses for 30 minutes each morning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decrease evening blue light
Description: Participants will wear tinted glasses that block blue wavelength light for 2 hours before bed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep scheduling
Description: Participants will advance their weekday bedtime and maintain their weekday risetime on weekends

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitor sleep, mood, and substance use
Description: Participants will monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraphy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitor sleep, mood, and substance use
Description: Participants will monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraphy
Study: NCT02469961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Participants will receive an interscalene block and will be sedated with Dexmedetomidine and compared to sedation with propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Participants will receive an interscalene block and be sedated with Propofol and compared to sedation with Dexmedetomidine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: Interscalene block is used for the main anesthetic for the case
Study: NCT00391638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRUVADA (EMTRICITABINE + TENOFOVIR DF)
Description: Truvada ® (200 mg tablet of 300 mg of emtricitabine + tenofovir DF) Dosage 1 tablet taken orally once a day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGASYS 180μg (Interféron pégylé alpha -2a)
Description: Pegasys ® injection 180μg Dosage: A subcutaneous injection per week
Study: NCT03826953

Intervention type: OTHER
Group type: OTHER
Intervention: Nurse Led Allergy Clinic
Description: Project to investigate if it is feasible to establish a nurse-led primary care-based allergy clinic intervention in NHS Lothian, and to understand the acceptability and estimate the impact of this service on improving access and outcomes in patients with allergic conditions.WE will undertake a mixed-methods longitudinal evaluation of the community-based nurse-led allergy clinic.
Study: NCT01174784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chronic TOtAl OcclusioN CrossiNg with thE WildCat CatheTer
Description: A Non-Randomized Study of the Avinger Wildcat™ used to Cross Chronic Total Occlusions in the Superficial Femoral and Popliteal Arteries